| Epidaza (chidamide) / Chipscreen |
ChiCTR-ONC-12002283: Phase Ib Clinical Trial of Chidamide Combined With Paclitaxel and Carboplatin Chemotherapy in Patients with Advanced Non–Small-Cell Lung Cancer |
|
|
| Completed | 1 | 18 | | Paclitaxel 175mg/m2 and Carboplatin AUC=5mg/ml·min once every 3 weeks Chidamide TIW escalated from 20mg | Cancer Hospital, Chinese Academy of Medical Sciences; Chipscreen Biosciences, Ltd., Chipscreen Biosciences, Ltd. | Advanced Non Small Cell Lung Cancer (NSCLC) | | | | |
ChiCTR2000040043: A phase I clinical study of the safety, tolerability, pharmacokinetics and efficacy of Azacitidine for injection combined with Chidamide in patients with relapsed/refractory T-cell lymphoma |
|
|
| Not yet recruiting | 1 | 17 | | Dose group 1: azacitidine 50mg/m2, iv, d1-7; Chidamide 20mg, po, biw, taking the medicine for 3 weeks; 4 weeks as a cycle ;Dose group 2: azacitidine 75mg/m2, iv, d1-7; Chidamide 20mg, po, biw, taking the medicine for 3 weeks; 4 weeks as a cycle ;Dose group 3: azacitidine 50mg/m2, iv, d1-7; Chidamide 30mg, po, biw, taking the medicine for 3 weeks; 4 weeks as a cycle ;Dose group 4: Azacytidine 75mg/m2, iv, d1-7; Chidamide 30mg, po, biw, taking the medicine for 3 weeks; 4 weeks as a cycle; ;RP2D | Tianjin Cancer Hospital; Tianjin Cancer Hospital, Tianjin Cancer Hospital | T cell lymphoma | | | | |
| Recruiting | 1 | 30 | RoW | Tucidinostat and etoposide | Yizhuo Zhang | Neuroblastoma in Children | 06/24 | 12/24 | | |
NCT05281276: Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC) |
|
|
| Recruiting | 1 | 12 | RoW | chidamide, tucidinostat, HBI-8000, celecoxib, Celebrex | Taipei Medical University Shuang Ho Hospital | Metastatic Colorectal Cancer | 12/24 | 12/24 | | |
NCT05659992: Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 30 | RoW | azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte | Chinese PLA General Hospital | Acute Myeloid Leukemia | 01/24 | 01/24 | | |
ChiCTR2200065634: One arm open phase I clinical study of Venetoclax combined with CACAG regimen in the treatment of acute myeloid leukemia |
|
|
| Recruiting | 1 | 30 | | 1.azacytidine (75mg/m2/day, days 1 to 7). 2.cytarabine (75mg/m2 bid, days 1 to 5). 3.aclamycin (10mg/m2/day, day1,3,5). 4.Chidamide (30mg/day , days 0,3). 5.venetoclax (100mg day 1, 200 mg day 2, 400mg days 3 to 14 ). 6.granulocyte colony-stimulating factor (5ug/kg/day, day 0 until agranulocytosis recovery | Chinese PLA General Hospital; Chinese PLA General Hospital, Fully self-raised | acute myeloid leukemia | | | | |
ChiCTR2200058569: Safety and efficacy of histone deacetylase inhibitors (chidamide) in combination with abiraterone in the treatment of metastatic castration-resistant prostate cancer (mCRPC): a single-arm, open phase, Ib clinical study study |
|
|
| Recruiting | 1 | | | Citabenamine (20mg) in combination with abiraterone ;Citabenamine (25mg) in combination with abiraterone ;Citabenamine (30mg) in combination with abiraterone | Sun Yat-sen University Cancer Center ; Sun Yat-sen University Cancer Center, Sun Yat-sen University Cancer Center | prostatic cancer | | | | |
NCT05586841: Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study |
|
|
| Not yet recruiting | 1 | 30 | RoW | Dalpiciclib, SHR6390, Chidamide | Beijing 302 Hospital | HR+/HER2- Advanced Breast Cancer | 11/24 | 11/25 | | |
ChiCTR2300067674: An Exploratory Study on Individualized Treatment of Chidamide Combined with Chemotherapy in Children with Acute Myeloid Leukemia |
|
|
| Not yet recruiting | 1 | 9 | | Cladribine + Homoharringtonine + cytarabine + Granulocyte stimulating factor + Chidamide | Division of Pediatric Blood Diseases Center State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences; Division of Pediatric Blood Diseases Center State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences, No | AML | | | | |
